Weight Loss Injections: A Complete Guide to Your Options in 2025

Injectable weight loss medications have fundamentally changed what's possible in obesity medicine. Where diet and exercise alone previously left most people losing just 3–5% of body weight, today's medications can deliver 15–22% — numbers that rival bariatric surgery. If you've been curious about what's available, how they differ, and whether you qualify, this is your comprehensive guide.

Why Injectable Medications Work So Well

For decades, the prevailing narrative around obesity was a simple calories-in, calories-out equation — a failure of willpower. Science has shifted that understanding dramatically. Obesity is now recognized as a complex, chronic disease driven largely by biology: hormones, genetics, gut microbiome, and neurochemical set points all influence body weight in ways that conscious willpower struggles to override.

Injectable medications work at the hormonal level, targeting pathways that govern hunger, satiety, blood sugar regulation, and energy expenditure. Rather than fighting the body's biology, they work with it — which is why they're so much more effective than traditional approaches.

GLP-1 Receptor Agonists: How They Work

The majority of injectable weight loss medications belong to a class called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the gut after eating. It plays several roles:

• Signals the brain's hypothalamus to reduce appetite and increase feelings of fullness
• Slows gastric emptying (food moves through the stomach more slowly, prolonging satiety)
• Stimulates insulin secretion in response to elevated blood sugar
• Reduces glucagon release, preventing excess glucose production by the liver

GLP-1 receptor agonists are synthetic molecules that mimic and amplify these natural signals. They have a longer half-life than natural GLP-1 (which breaks down within minutes), providing sustained appetite suppression and blood sugar control around the clock.

The Weight Loss Injections Available in 2025

1. Semaglutide (Ozempic / Wegovy)

Semaglutide was the first GLP-1 medication to generate widespread cultural attention for weight loss. Originally approved for type 2 diabetes as Ozempic, the higher-dose formulation was approved specifically for obesity management as Wegovy in 2021.

How it works: Semaglutide binds to GLP-1 receptors in the brain and pancreas, reducing appetite and slowing gastric emptying. It's administered as a once-weekly subcutaneous injection that most patients self-administer in the abdomen, thigh, or upper arm.

Clinical results: In the STEP 1 trial, participants on semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks — compared to 2.4% in the placebo group. More than 86% of participants achieved at least 5% weight loss, and about 32% achieved 20% or greater weight loss.

Dosing: Started at 0.25mg weekly, titrated over 16–20 weeks to the 2.4mg maintenance dose (Wegovy) or up to 1mg for diabetes management (Ozempic).

Learn more: Semaglutide at Truventa Medical

2. Tirzepatide (Mounjaro / Zepbound)

Tirzepatide represents the next generation of incretin-based therapies. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP amplifies the insulin response and may have additional effects on fat cell metabolism.

Originally approved for diabetes as Mounjaro, the obesity indication was approved as Zepbound in late 2023.

Clinical results: The SURMOUNT-1 trial delivered stunning results. Participants on tirzepatide 15mg lost an average of 22.5% of body weight over 72 weeks — nearly matching what's achievable with sleeve gastrectomy (bariatric surgery). Over 90% of participants lost at least 5% of body weight, and more than half lost 20% or more.

Dosing: Started at 2.5mg weekly, titrated over 20 weeks to the 10mg or 15mg maintenance dose.

Learn more: Tirzepatide at Truventa Medical

3. Liraglutide (Saxenda)

Liraglutide was the first GLP-1 receptor agonist approved specifically for weight management (2014) and remains available, though it has largely been superseded by newer, more effective options.

Clinical results: In the SCALE Obesity trial, liraglutide 3mg produced average weight loss of 8.4% over 56 weeks — meaningful, but substantially less than semaglutide or tirzepatide.

Dosing: Daily injection (unlike the weekly dosing of semaglutide and tirzepatide), which many patients find less convenient. Titrated over 5 weeks to the 3mg maintenance dose.

While liraglutide is a valid option for some patients, most prescribers now favor semaglutide or tirzepatide for their superior efficacy and more convenient weekly dosing.

Head-to-Head Comparison

Medication	Brand Names	Target(s)	Dosing Frequency	Average Weight Loss	FDA Approved for Obesity
Semaglutide	Wegovy, Ozempic	GLP-1	Once weekly	~15%	Yes (Wegovy)
Tirzepatide	Zepbound, Mounjaro	GLP-1 + GIP	Once weekly	~22%	Yes (Zepbound)
Liraglutide	Saxenda	GLP-1	Once daily	~8%	Yes (Saxenda)

Who Qualifies for Weight Loss Injections?

FDA approval criteria for GLP-1 obesity medications are:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) with at least one weight-related comorbidity such as:
  • Type 2 diabetes or prediabetes
  • High blood pressure (hypertension)
  • High cholesterol (dyslipidemia)
  • Obstructive sleep apnea
  • Cardiovascular disease

These medications are intended for adults and are prescribed as part of a comprehensive weight management program that includes dietary counseling and physical activity guidance.

Contraindications (reasons you may not qualify) include:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• History of pancreatitis
• Pregnancy or breastfeeding
• Certain gastrointestinal conditions

A full medical evaluation by a licensed provider is necessary to determine if these medications are right for you. At Truventa Medical, our physicians review your complete health history before issuing any prescription.

Common Side Effects and How to Manage Them

GLP-1 medications are generally well-tolerated, but gastrointestinal side effects are common, especially during the dose escalation phase:

• Nausea: Most common side effect, particularly in the first weeks. Usually improves as the body adjusts. Strategies: eat smaller meals, avoid fatty or spicy foods, take medication at bedtime.
• Vomiting: Less common, more likely with faster titration. Slowing the dose increase typically resolves it.
• Diarrhea or constipation: Variable; staying hydrated and increasing fiber helps.
• Reduced appetite: Expected and beneficial for weight loss, though you must ensure adequate nutrition.
• Fatigue: Usually transient and improves after the adjustment period.

Rare but serious side effects requiring immediate medical attention include severe abdominal pain (possible pancreatitis), vision changes, signs of thyroid tumors (neck lump, difficulty swallowing), and severe allergic reactions.

How to Access Weight Loss Injections via Telehealth

In-person visits to obesity medicine specialists can involve long wait times and high costs. Telehealth has made access to these medications significantly faster and more convenient. Through a platform like Truventa Medical, the process typically looks like this:

1. Complete a health questionnaire: Answer questions about your medical history, current medications, and weight loss goals. Takes about 10 minutes online.
2. Physician review: A board-certified physician reviews your information and may request lab work (often available at local labs or through at-home testing).
3. Prescription issued: If you qualify, a prescription is sent to a licensed pharmacy — brand-name or compounded formulations depending on availability.
4. Medication delivered: Medications are shipped directly to your door, often within a few business days.
5. Ongoing support: Truventa providers monitor your progress, adjust dosing as needed, and provide guidance throughout your treatment.

No insurance is required, and Truventa's transparent pricing makes budgeting straightforward.

A Note on Compounded Semaglutide and Tirzepatide

Due to persistent brand-name shortages, FDA-registered 503B compounding pharmacies have been producing compounded semaglutide and tirzepatide. These compounded versions have made the medications accessible to far more patients at lower cost. However, supply is subject to change based on FDA shortage designations, and quality varies by pharmacy. Reputable telehealth providers work exclusively with licensed, accredited compounding pharmacies.

Always work with a licensed provider rather than seeking these medications from unregulated online sources.

Frequently Asked Questions

Do I have to stay on weight loss injections forever?

Not necessarily, but it's an important consideration. Clinical trials show that most people regain a significant portion of lost weight after stopping GLP-1 medications. For many patients, ongoing use (at a reduced maintenance dose) is the most effective long-term strategy. This is similar to how other chronic conditions like high blood pressure or diabetes require ongoing management. Discuss long-term planning with your provider.

Are weight loss injections safe for people without diabetes?

Yes. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved specifically for weight management in non-diabetic patients who meet BMI criteria. The clinical trials demonstrating efficacy and safety were conducted primarily in people without diabetes.

How soon will I see results?

Many people notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically becomes apparent in the first month, though the dose is still low during this period. The most significant weight loss occurs at higher maintenance doses (months 3–6 and beyond). On average, most patients lose 1–2 lbs per week at therapeutic doses.

What's the difference between Ozempic and Wegovy?

Both contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes management (max dose 2mg weekly) while Wegovy is FDA-approved for chronic weight management (max dose 2.4mg weekly). Wegovy's slightly higher maximum dose contributes to greater weight loss results.

Can I get weight loss injections if I live in a rural area?

Yes — telehealth makes this possible. Truventa Medical serves patients in all 50 states, and medications can be shipped directly to your home. You don't need to live near a specialist or major city to access these treatments.